Astellas Pharma
| Astellas Pharma
|
|
|---|---|
 |
|
| legal form | GmbH |
| Seat |
Munich , Germany
|
| management | Nicolaas Stander |
| Number of employees | 333 |
| sales | EUR 388 million |
| Branch | pharmacy |
| Website |
astellas.com astellas.de |
| As of March 31, 2016 | |
The Astellas Pharma GmbH is a German, a research-based pharmaceutical company and a 100% subsidiary of the Japanese company Astellas , which with Takeda Pharmaceutical and Daiichi Sankyo - one of the three largest Japanese pharmaceutical companies - decreasing by approximately 8.5 billion euros.
History in Germany
In January 2002, Klinge Pharma became a wholly-owned subsidiary of Fujisawa and was renamed Fujisawa Deutschland GmbH. Astellas Pharma GmbH was founded in 2005 as a German subsidiary of Astellas Pharma Inc., Tokyo from the companies Yamanouchi Pharma GmbH and Fujisawa Deutschland GmbH.
Your seat in Germany is Munich; The general manager is Nicolaas Jacobus Stander.
Immunosuppression
One of the main research areas of the Astellas is immunosuppression , a process in which immunological processes are suppressed. Unwanted reactions of the immune system must z. B. be inhibited after organ transplants . The body reacts to the new, i. H. "foreign" organ with a natural reaction to rejection. This can be prevented with the help of immunosuppression.
Medication
- Advagraf ( Tacrolimus (FK 506) ), indication area: immunosuppression, belongs to the so-called basic immunosuppressants in transplant medicine alongside ciclosporin , which form the basis of immunosuppressive therapy after transplants. Tacrolimus is also a combination partner for other immunosuppressants. Advagraf is the once-daily dosage form.
- Betmiga ( mirabegron ) is a selective beta-3 adrenoceptor agonist used to treat symptoms of overactive bladder (OAB) .
- Bronchoretard is a bronchospasmolytic with the active ingredient theophylline . The main focus of therapy is the treatment of bronchial asthma and chronic obstructive bronchitis (COPD) .
- Dificlir ( fidaxomicin ) is an antibiotic used to treat Clostridium difficile infection .
- Eligard ( leuprorelin ) is an LHRH agonist for the treatment of hormone-dependent advanced prostate cancer .
- Formotop contains the active ingredient formoterol , a long-acting β2 sympathomimetic , and is used for bronchial asthma and COPD.
- Modigraf is a tacrolimus formulation especially for children. As granules for the preparation of an oral suspension, it is available for immunosuppression in children after heart, liver and kidney transplants.
- Mycamine ( Micafungin ) is an antifungal agent that belongs to the group of echinocandins and u. a. is used for the treatment and / or prophylaxis of invasive candidiasis .
- Omnic Ocas ( tamsulosin ), indication area: urology , is used to treat benign prostate enlargement (BPH) to alleviate the symptoms of a urinary outflow disorder. These symptoms include difficult and frequent nocturnal urination. If the prostate is already greatly enlarged, urinary incontinence can even occur.
- Prograf (Tacrolimus (FK 506)), indication area: immunosuppression, belongs to the so-called basic immunosuppressants in transplant medicine alongside ciclosporin , which form the basis of immunosuppressive therapy after transplants.
- Protopic (tacrolimus) is a topical immunomodulator (TIM) and is used as a cortisone-free treatment alternative for neurodermatitis .
- Qutenza ( capsaicin ) is used as a cutaneous patch to treat peripheral neuropathic pain in adults. Qutenza can be used as monotherapy or in combination with other medicines for pain relief.
- Venostasin with the active ingredient horse chestnut seed extract is used for swelling, tension and pain in the legs due to water retention in the tissue (edema) and / or a weak vein.
- Vesicure ( Solifenacin succinate ) is a selective muscarinic receptor antagonist used to treat symptoms of overactive bladder (OAB), urge incontinence and / or pollakiuria and imperative urination.
- Vomex A is used for the prophylaxis and symptomatic therapy of nausea and vomiting of various pathogenesis , especially of kinetoses.
- Xtandi ( enzalutamide ) is an androgen receptor signaling pathway inhibitor used in the treatment of metastatic castration-resistant prostate cancer after prior chemotherapy .
Research awards
DTG Research Prize Immunosuppression
Every year, the company sponsors the DTG Immunosuppression Research Prize, which was originally launched by Fujisawa GmbH . The prize is awarded to theoretically and clinically active scientists whose scientific work deals with immunosuppression with tacrolimus . It consists of a main prize endowed with 5,000 euros and two sponsorship prizes endowed with 2,500 euros each.
Astellas Research Prize Dermatology
The Dermatology Research Prize has been awarded every two years since 2007 and is awarded to scientists working in Germany for scientific research work in the field of inflammatory skin diseases. It consists of a main prize endowed with 5,000 euros and a sponsorship prize endowed with 2,500 euros.
Prostate Cancer Research Prize
Astellas annually supports the "Prostate Cancer Research Prize" advertised by the German Society for Urology (DGU) . The prize donated by Astellas Pharma is endowed with € 10,000 and will be awarded at the DGU's annual meeting.
Web links
Individual evidence
- ↑ a b Astellas Pharma GmbH - Annual financial statements for the business year from April 1, 2015 to March 31, 2016. May 16, 2017. Retrieved December 21, 2017 .
- ↑ Astellas Corporate WebSite: Astellas Financial Highlights . Retrieved January 19, 2015.
- ^ Website of the German company
- ↑ a b c Research Awards from Astellas , retrieved from the German website